Ramsay Health Care (RHC) – NEUTRAL
|Date of Report||ASX||Price||Price Target||Analyst Recommendation|
|Date of Report|
|Sector : Healthcare||52-Week Range: A$53.01 – 71.15|
|Industry: Hospitals||Market Cap: A$11,009.4m|
We rate RHC as a Neutral for the following reasons:
- Largest private hospital operator in Australia, with attractive industry fundamentals (aging population). Favorable macro industry trends: ageing and growing population, proliferation of chronic disease, and increasing innovation, treatment, and technologies to drive demand to private hospitals.
- Supportive government policy (tax incentive for people to get private health insurance).
- Ongoing brownfield program driving earnings and offshore earnings growth.
- Significant operations offshore provide opportunity for growth outside of domestic market.
- Attractive industry dynamics and high barriers to entry
We see the following key risks to our investment thesis:
- Short term weakness as per management’s FY19 guidance.
- Competitive risk (new hospitals, new beds), from listed and unlisted hospital operators.
- Brownfield projects fail to deliver the earnings uplift.
- Cost pressures (negotiating price increases with private health insurance companies).
- Change to government policy on private health insurance.
- Execution risk (able to get the uplift in earnings from brownfield projects).
- Earnings growth in offshore operations disappoint.
- Currency risk.
Figure 1: RHC Revenue by Segment
Figure 2: RHC EBITDA by Segment
RHC reported FY18 results in line with its pre-announced disappointing June 2018 trading update where the Company revised guidance.
Indeed, management noted “as disclosed to the market in June, our FY18 results were impacted by the significant downturn in NHS volumes in our UK business as well as softer growth rates in our Australian business and the decision to temporarily slow down the rollout of the Ramsay Pharmacy franchise network while we invest in infrastructure and resources to successfully scale this franchise business for the long term”.
Key highlights include:
1. Core Net Profit After Tax of $579.3m, up +6.8% increase on the previous corresponding period, which equates to core EPS of 279.8cps, up +7.0% on the 261.4 cents recorded in pcp and in line with the revised guidance provided in June 2018.
2. fully-franked final dividend of 86.5 cents, up +6.1% on the pcp, taking the full year dividend to 144.0 cents fully-franked, up +7.1% on the prior year.
3. Reported NPAT and after net non-core items of $388.3m, was down 20.6% on the prior year which reflect net non-core items of $191.0m (net of minorities and net of tax) recognised (mainly due to Ramsay UK recognising an onerous lease provision and asset write downs related to certain UK sites of $122.0m (net of tax) and Ramsay Générale de Santé (RGdS) recognising restructuring costs of $29.9m).
4. RHC has enough balance sheet flexibility to fund “continuing demand for brownfield capacity expansion, future acquisitions and ongoing working capital needs” with consolidated leverage ratio of 2.3x, well within internal parameters.
Longer term, we don’t doubt the quality of RHC (at the management level and assets) however, we yield to management’s warnings of short term weakness. We maintain our Neutral recommendation.
- Asia-pacific (~65% of earnings). In terms of Australia, revenue was up +5.5% to $4.9bn and EBITDA up +12.1% to $896.0m. In our view, these were solid outcomes considering RHC’s hospitals were able to maintain admissions growth above the industry despite concerns over affordability of private health insurance. Projects with a gross capital investment of $171m were completed (which includes seven theatres and 21 consulting suites). RHC’s board also approved a record $325m in new projects (including 229 net beds and 24 theatres). RHC’s equity accounted share of Asian joint venture net profits was $16.8m, up 27.7%.
- France (~29% of earnings). Revenue was up +0.3% to €2.2bn and EBITDAR down -0.6% to €445.7m. These disappointing results were as expected by the market given the persisting negative tariff environment. The programme to centralise non-core hospital functions to a shared service centre announced at the half year results remains on track and will take three to four years.
- UK (~6% of earnings). Revenue was down -5.2% to £424.2m and EBITDAR down -9.8% to £102.7m as demand management strategies had a negative impact on NHS volumes despite positive tariff adjustments.
- Weak short-term outlook and guidance but longer-term fundamentals intact. Management guided that “based on current operating conditions in each of our core markets and barring unforeseen circumstances, in FY19, Ramsay is targeting positive Core EPS growth of up to 2%, adversely impacted by anticipated higher interest and tax in FY19. This corresponds to Core EBITDA growth for the Group of 4% to 6%”. Further we note, management is expecting “underlying earnings growth to be subdued driven by a combination of challenging circumstances in the UK, a slower rate of growth in Australia, and a neutral outlook in France”. Australian brownfield programme will deliver $242m in completed projects in FY19 and includes net 216 beds and 15 operating theatres, and “are anticipated to contribute materially to growth beyond FY19”.
- Bid for Capio AB (Capio). In July 2018, RHC’s 50.9% owned French subsidiary, RGdS, launched an unsolicited takeover bid for Nasdaq Stockholm listed, pan-European healthcare company, Capio. Offer completion is subject to conditions customary for public offers in Sweden, including, among others, antitrust and regulatory approvals and that the Offer is accepted by shareholders to such an extent that RGdS becomes owner of more than 90% of shares in Capio.
RHC FY18 Results Summary…
Figure 3: RHC FY18 results summary
Figure 4: RHC Financial Summary
Source: BTIG estimates, Company, Bloomberg
Ramsay Health Care Ltd (RHC) provides healthcare services. RHC operates 238 hospitals, day surgery centres, treatment facilities, rehabilitation & psychiatric units across six countries. The company has operations in Australia (71), United Kingdom (36), Italy (1), France (123), Malaysia (3) and Indonesia (3).
Recommendation Rating Guide
|Recommendation Rating Guide||Total Return Expectations on a 12-mth view|
|Speculative Buy||Greater than +30%|
|Buy||Greater than +10%|
|Neutral||Greater than 0%|
|Sell||Less than -10%|
Reach Markets Disclaimer
Reach Markets Pty Ltd (ABN 36 145 312 232) is a Corporate Authorised Representative of Reach Financial Group Pty Ltd (ABN 17 090 611 680) who holds Australian Financial Services Licence (AFSL) 333297. Please refer to our Financial Services Guide or you can request for a copy to be sent to you, by emailing [email protected].
Read our full disclaimer here >
This publication contains general securities advice. In preparing the advice, Reach Markets Australia has not taken into account the investment objectives, financial situation and particular needs of any particular person. Before making an investment decision on the basis of this advice, you need to consider, with or without the assistance of a securities adviser, whether the advice in this publication is appropriate in light of your particular investment needs, objectives and financial situation. Reach Markets Australia and its associates within the meaning of the Corporations Act may hold securities in the companies referred to in this publication. Reach Markets Australia does, and seeks to do, business with companies that are the subject of its research reports. Reach Markets Australia believes that the advice and information herein is accurate and reliable, but no warranties of accuracy, reliability or completeness are given (except insofar as liability under any statute cannot be excluded). No responsibility for any errors or omissions or any negligence is accepted by Reach Markets Australia or any of its directors, employees or agents. This publication must not be distributed to retail investors outside of Australia.
It is recommended that you seek independent advice and read the relevant Product Disclosure Statement before making a decision in relation to any investment. Any advice contained in this communication is general and has not taken into account the investment objectives, financial situation and particular needs of any particular person.
Banyan Tree Disclaimer
This document is provided by Banyan Tree Investment Group (ACN 611 390 615; AFSL 486279) (“Banyan Tree”).
The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require. The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice.
The material in this document has been obtained from sources believed to be true but neither Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy, or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and Banyan Tree is not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.
Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Banyan Tree does, and seeks to do, business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.
Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Banyan Tree, its associates, officers, directors, employees and agents. Except for any liability which cannot be excluded, Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material. Recipients of this document agree in advance that Banyan Tree is not liable to recipients in any matters whatsoever otherwise recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Banyan Tree does not guarantee reliability and accuracy of the material contained in this document and is not liable for any unintentional errors in the document.
The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Banyan Tree.
This document has been commissioned by Reach Markets Australia Pty Ltd and provided by Banyan Tree Investment Group (ACN 611 390 615; AFSL 486279) (“Banyan Tree”).